Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS

Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS

BackgroundHemophagocytic lymphohistiocytosis (HLH) is a fatal immunological syndrome resulting from excessive production of inflammatory cytokines. The conventional therapies for HLH, which are based on cytotoxic agents, are not always efficacious and safe, especially in patients with severe immunod...

Full description

Bibliographic Details
Main Authors: Xiang Liu, Xueling Zhu, Xiaotang Zhou, Yirui Xie, Dairong Xiang, Zhikai Wan, Ying Huang, Biao Zhu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Immunology
Subjects:
ruxolitinib
hemophagocytic lymphohistiocytosis
acquired immune deficiency syndrome
cytokines
inflammation
therapeutics
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1012643/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1012643/full

Similar Items